SciTech Given IRB Approval to enter clinic at Rush University for nanoFenretinide treatment of NHL
SciTech's Investigational New Drug Application (IND) for ST-001 nanoFenretinide treatment of T-cell non-Hodgkin's lymphoma (NHL) was accepted last December. Additionally, the FDA has granted Orphan Drug Designation status for ST-001 in the treatment of two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Solid preclinical and clinical data makes the case for the use of fenretinide in the treatment of additional blood disorders and solid tumors such as small cell lung, breast, pancreatic, neuroblastoma and other cancers.
For ST-001 nanoFenretinide investment and partnering opportunities contact Earle Holsapple | +1-313-263-4887 | email@example.com
About SciTech Development
SciTech Development, LLC is a clinical stage, specialty pharmaceutical development company currently bringing to market a proven drug for diseases with otherwise limited therapeutic options. SciTech Development is headquartered in the metropolitan Detroit, Michigan area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland. Additional information regarding SciTech's nanoparticle technology and ST-001 nanoFenretinide drug product is available from SciTech Development, LLC by calling +1-313-938-5517 or online at https://www.scitechdevelopment.com/
About Rush University Medical Center (RUMC)
Named a top U.S. hospital by U.S. News & World Report, Rush University Medical Center is one of Chicago's finest academic medical centers and is comprised of Rush University Medical Center, Rush University, Rush Oak Park Hospital and Rush Health. Additional information regarding RUMC is available online at www.rush.edu
SciTech Development, LLC